31 things you should remove from your résumé immediately

Posted · Add Comment

Jacquelyn Smith and Rachel Gillett     On average, hiring managers get 75 résumés per position they post, according to a study from CareerBuilder.com — so they don’t have the time or resources to look at each one closely, and they typically spend about six seconds on their initial “fit/no fit” decision. If you want to […]

Bill Gates, Warren Buffett, and Oprah Winfrey All Use the 5-Hour Rule Top business leaders often spend five hours per week doing deliberate learning.

Posted · Add Comment

Bill Gates, Warren Buffett, and Oprah Winfrey All Use the 5-Hour Rule Top business leaders often spend five hours per week doing deliberate learning. In the article “Malcolm Gladwell Got Us Wrong,” the researchers behind the 10,000-Hour Rule set the record straight: Different fields require different amounts of deliberate practice in order for someone to become […]

Top 5 Things NOT To Say In An Interview

Posted · Add Comment

Top 5 Things NOT To Say In An Interview James Caan CBE A lot of my blogs in the past have highlighted my personal top tips in an interview scenario, the right questions to ask, the right kind of answers to respond to interviewer questions, the expected etiquette of interviewees, the right way to prepare […]

Avoid These 10 Resume Mistakes

Posted · Add Comment

Avoid These 10 Resume Mistakes by Katharine Hansen, Ph.D. As a resume writer, I see hundreds of resumes, and the vast majority of them are much weaker than they could be. I see the same mistakes over and over. This article describes the 10 I see most often. All are easy to fix. Don’t Make […]

Keytruda

Posted · Add Comment

Keytruda, the drug that helped Jimmy Carter, also protects against lung cancer Researchers have stopped a study of a new lung cancer drug, saying it’s so effective they want to offer it to all the patients in the trial. “This is a huge deal for people with what we call non-small cell lung cancer, which […]

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer Merck’s flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with newly diagnosed non-small cell lung cancer compared to chemotherapy, the company said Thursday.

Posted · Add Comment

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer Merck’s flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with newly diagnosed non-small cell lung cancer compared to chemotherapy, the company said Thursday. Merck’s (MRK) flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with […]